由雄激素受体交互激活域和小分子药物形成的共价附加物仍然是无序的
1Department of Chemistry, Dartmouth College, Hanover, New Hampshire 03755, United States.
Journal of chemical information and modeling
|May 30, 2025
概括
针对内在无序的蛋白质的小分子形成共价添加物,改变蛋白质结构. 分子动力学模拟显示,这些附加物稳定了崩的螺旋形状,有助于开发强大的抑制剂,用于诸如前列腺癌等疾病.
科学领域:
- 生物化学 生物化学
- 结构生物学 结构生物学
- 计算化学的计算化学
背景情况:
- 内在失序蛋白 (IDP) 在人类疾病中至关重要.
- 针对雄激素受体交换活化域 (AR-TAD) 的小分子正在进行针对割抵抗性前列腺癌的临床试验.
- 这些分子与AR-TAD氨酸残留物形成共价添加物,但它们的结构影响尚不清楚.
研究的目的:
- 研究由小分子 (EPI-002,EPI-7170) 与内在无序的雄激素受体交换活化域 (AR-TAD) 的共价结合引起的构造变化.
- 提供原子详细的洞察力,了解共价 adducts 内的蛋白质-配体相互作用.
- 为IDPs设计更有效的共价抑制剂提供信息.
主要方法:
- 全原子分子动力学 (MD) 计算机模拟.
- 用EPI-002和EPI-7170.0模拟AR-TAD的共价添加物.
- 与共价和非共价连接体结合状态之间的构造集的比较.
主要成果:
- 在AR-TAD的共价添加物中,呈现出异质和无序的形状组合.
- 与非共价结合相比,EPI-002和EPI-7170的共价结合增加了与非共价结合相比,崩的螺旋式AR-TAD形状的数量.
- 独特的蛋白质-连接体相互作用网络稳定了这些崩的形状,形成了共价 adducts.
结论:
- 共价性修饰显著改变了无序的AR-TAD的结构格局.
- 了解这些改变的组合和稳定相互作用是设计强有力的共价抑制剂的关键.
- 这项研究提供了一个详细的分子视角,对国际DPs的共价抑制.
更多相关视频
相关概念视频
Drug-Receptor Bonds
3.3K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
3.3K
Drug-Receptor Interactions
6.1K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
6.1K
Drug-Receptor Interaction: Agonist
2.9K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.9K
The Two-State Receptor Model
2.5K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
2.5K
Assembly of Signaling Complexes
6.0K
Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
6.0K
Targets for Drug Action: Overview
7.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.5K


